Compare Recursion Pharmaceuticals Inc (RXRX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.67. Which is the better fit depends on your goals.
| RXRX | YMAG | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $6.79 | $15.98 |
52-Week Low | $2.84 | $11.00 |
Enterprise Value | $946.50M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
